RxDoctor Payments Data

Andy Green, MD

Dermatology · Miami, FLNPI 1588610232

Payments from drug & device makers

$1,879in general payments, 2019–2025

Across 33 payments — averaging $56.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$862
  • Regeneron Healthcare Solutions, Inc.$350
  • Dermavant Sciences, Inc.$161
  • Incyte Corporation$128
  • Dermira, Inc.$125
  • Amgen$118
  • plus $135 from 2 others

What the payments were for

  • Food & beverage$1,78195%
  • Education$985%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer15$862
Regeneron Healthcare Solutions, Inc.12$350
Dermavant Sciences, Inc.1$161
Incyte Corporation1$128
Dermira, Inc.1$125
Amgen1$118
Pear Therapeutics (US), Inc.1$112
AbbVie1$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,879 in reported general payments places this provider in the 40th percentile of 1,147 dermatology providers in Florida.

See all dermatology providers in Florida

Medicare billing

Part B allowed, 2024
$55,845
Medicare patients
117
Services billed
809

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnbrelEtanercept11$79,868
Clobetasol Propionate317$11,503
Ketoconazole687$10,836
Triamcinolone Acetonide817$6,763
Fluocinolone Acetonide204$6,482
Ammonium Lactate210$5,461
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet118$4,220
CiclopiroxCiclopirox Olamine61$3,620
Levocetirizine Dihydrochloride223$2,854
Tacrolimus22$2,751
Clindamycin Phosphate99$2,486
Metronidazole36$1,664
Betamethasone Dipropionate33$1,635
Fluocinolone AcetonideFluocinolone/Shower Cap27$1,540
Hydrocortisone215$1,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel$118$79,86811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,147 dermatology providers in Florida.

Other dermatology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →